NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML

Area of Science:

• Molecular Biology
• Cancer Genetics
• Hematology

Background:

• Nucleophosmin (NPM1) is a key nucleocytoplasmic shuttling protein regulating cellular processes.
• NPM1 localization, crucial for its function, depends on specific tryptophan residues.
• NPM1 mutations in acute myeloid leukemia (AML) cause cytoplasmic delocalization, but variant significance is debated.

Purpose of the Study:

• To investigate the biological and clinical significance of different NPM1 mutation variants in AML.
• To explore the impact of NPM1 mutations on HOXA and HOXB gene expression.
• To determine how NPM1 mutation status affects AML cell sensitivity to chemotherapy and Venetoclax.

Main Methods:

• Analysis of HOXA and HOXB gene expression profiles in AML patients with different NPM1 mutations.
• Expression of NPM1 A-like (loss of two Trp) and non-A-like (loss of one Trp) mutated vectors in AML cell lines.
• Assessment of p14ARF/p21/p53 pathway deregulation and treatment sensitivity.

Main Results:

• Differential HOXA and HOXB gene expression observed between A-like and non-A-like NPM1 mutations.
• NPM1 partially retained nucleolar localization in non-A-like mutated cells.
• A-like NPM1 mutations led to HOXA5, HOXA10, HOXB5 hyper-expression, p14ARF/p21/p53 pathway deregulation, and reduced sensitivity to chemotherapy and Venetoclax.

Conclusions:

• NPM1 mutational status significantly influences AML cell biology, including gene expression and pathway activation.
• The loss of one versus two tryptophan residues in NPM1 mutations has distinct biological consequences.
• Findings support further sub-classification of AML based on NPM1 mutation type for potential therapeutic management.